Toyota|$17.88 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.03 (¥3,960)+0.03%▲ (in JPY terms)
SoftBank|$30.63 (¥4,845)-2.00%▼ (in JPY terms)
MUFG|$21.99 (¥3,478)+0.09%▲ (in JPY terms)
Keyence|$514.64 (¥81,410)+0.80%▲ (in JPY terms)
Nintendo|$53.99 (¥8,541)+0.73%▲ (in JPY terms)
NTT|$1.11 (¥175)+0.34%▲ (in JPY terms)
Takeda|$39.47 (¥6,244)+0.34%▲ (in JPY terms)
Tokyo Electron|$65.43 (¥10,350)-2.63%▼ (in JPY terms)
Recruit|$118.69 (¥18,775)+1.93%▲ (in JPY terms)
ITOCHU|$14.67 (¥2,320)+1.58%▲ (in JPY terms)
Honda|$11.43 (¥1,808)+0.56%▲ (in JPY terms)
Shin-Etsu|$37.71 (¥5,966)-0.20%▼ (in JPY terms)
Tokio Marine|$3.51 (¥555)-0.61%▼ (in JPY terms)
Fast Retailing|$466.85 (¥73,850)-2.29%▼ (in JPY terms)
Toyota|$17.88 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.03 (¥3,960)+0.03%▲ (in JPY terms)
SoftBank|$30.63 (¥4,845)-2.00%▼ (in JPY terms)
MUFG|$21.99 (¥3,478)+0.09%▲ (in JPY terms)
Keyence|$514.64 (¥81,410)+0.80%▲ (in JPY terms)
Nintendo|$53.99 (¥8,541)+0.73%▲ (in JPY terms)
NTT|$1.11 (¥175)+0.34%▲ (in JPY terms)
Takeda|$39.47 (¥6,244)+0.34%▲ (in JPY terms)
Tokyo Electron|$65.43 (¥10,350)-2.63%▼ (in JPY terms)
Recruit|$118.69 (¥18,775)+1.93%▲ (in JPY terms)
ITOCHU|$14.67 (¥2,320)+1.58%▲ (in JPY terms)
Honda|$11.43 (¥1,808)+0.56%▲ (in JPY terms)
Shin-Etsu|$37.71 (¥5,966)-0.20%▼ (in JPY terms)
Tokio Marine|$3.51 (¥555)-0.61%▼ (in JPY terms)
Fast Retailing|$466.85 (¥73,850)-2.29%▼ (in JPY terms)

JP3160400002

2026-10-16 Eisai Co.,Ltd. “At the European Society for Medical Oncology (ESMO) Annual Meeting 2026, we will present further evidence in the field of oncology—new insights into Lenvima® (lenvatinib)-based combination therapy from the Phase III LITESPARK-011 and LITESPARK-012 clinical trials for advanced renal cell carcinoma, new findings from translational studies of advanced or recurrent endometrial cancer obtained from exploratory biomarker analysis of the Phase III LEAP-001 trial, and new findings from "Patients Raise Their Voices."”

by

2026-10-16 Eisai Co.,Ltd. “At the European Society for Medical Oncology (ESMO) Annual Meeting 2026, we w … 続きを読む

2026-09-28 Eisai Co.,Ltd. “The combination therapy of Lenvima® (lenvatinib) and Wellireg® (verzutifan) has been approved by the U.S. FDA for adult patients with previously treated advanced clear cell renal cell carcinoma. This approval is based on the results of the Phase III clinical trial "LITESPARK-011," which evaluated the combination therapy of Lenvima and Wellireg compared to cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC) who had previously received treatment with PD-1/PD-L1 inhibitors. The combination of Lenvima and Wellireg is the first combination therapy of a multi-target VEGFR tyrosine kinase inhibitor and an HIF-2α inhibitor to be approved in ccRCC patients.”

by

2026-09-28 Eisai Co.,Ltd. “The combination therapy of Lenvima® (lenvatinib) and Wellireg® (verzutifan) h … 続きを読む

2026-09-28 Eisai Co.,Ltd. “8,250 drinking cups donated to support lymphatic filariasis control efforts in Papua New Guinea—through an employee-participation "One-Coin Donation" project, in collaboration with JICA and Toyota Tsusho (PNG) Ltd., supporting local health and medical activities.”

by

2026-09-28 Eisai Co.,Ltd. “8,250 drinking cups donated to support lymphatic filariasis control efforts i … 続きを読む

2026-09-16 Eisai Co.,Ltd. “Rekenbi®, a subcutaneous injection formulation of the early-stage Alzheimer's disease treatment drug Rekenbi®, has received approval in Japan—the first and only home-administered anti-amyloid therapy for Alzheimer's disease in Japan.”

by

2026-09-16 Eisai Co.,Ltd. “Rekenbi®, a subcutaneous injection formulation of the early-stage Alzheimer&# … 続きを読む

2026-09-03 Eisai Co.,Ltd. “Rekenbi®, a subcutaneous injection formulation, has received approval in China as an initial treatment for early-stage Alzheimer's disease—the first and only home-administered anti-amyloid therapy for Alzheimer's disease, a progressive neurodegenerative disease, in China.”

by

2026-09-03 Eisai Co.,Ltd. “Rekenbi®, a subcutaneous injection formulation, has received approval in Chin … 続きを読む

2026-09-01 Eisai Co.,Ltd. “The Canadian Medicines Agency has published its final recommendation supporting public reimbursement for the early-stage Alzheimer's disease treatment Lekenbi® (lecanemab)—a significant step towards expanding access to Lekenbi for eligible individuals in Canada.”

by

2026-09-01 Eisai Co.,Ltd. “The Canadian Medicines Agency has published its final recommendation supporti … 続きを読む

Contact